Antipsychotic Medications: First and Second Generation Reference

Antipsychotic medications are a foundational class of psychiatric drugs used primarily to treat conditions involving psychosis — a state in which perception becomes disconnected from consensus reality. This reference covers both first-generation (typical) and second-generation (atypical) antipsychotics: what they are, how they act on the brain, where they fit clinically, and how prescribers navigate the real trade-offs between them. For anyone trying to understand a diagnosis or a treatment plan involving these medications, the distinctions matter considerably more than the marketing ever suggested.

Definition and scope

Antipsychotic medications are formally classified as dopamine receptor antagonists, though that description barely captures what the second generation does. The first antipsychotic, chlorpromazine, entered clinical use in 1952 after French surgeon Henri Laborit observed its unusual calming effects in surgical patients. That observation triggered one of the more consequential shifts in psychiatric history — within a decade, state hospital populations in the United States began declining for the first time since such institutions opened.

The medications divide into two broad generations:

First-generation antipsychotics (FGAs), also called typicals, include haloperidol (Haldol), chlorpromazine (Thorazine), fluphenazine, and perphenazine. These drugs were the only option available for roughly 40 years and remain in use — particularly haloperidol, which the World Health Organization continues to list on its Model List of Essential Medicines.

Second-generation antipsychotics (SGAs), also called atypicals, include clozapine, olanzapine, risperidone, quetiapine, aripiprazole, and ziprasidone. The FDA approved clozapine — the first atypical — in 1989, followed by a rapid expansion of the class through the 1990s and 2000s.

Both generations treat schizophrenia and psychotic disorders, the manic phase of bipolar disorder, and psychotic features in depression and mood disorders. SGAs have also expanded into augmentation therapy for treatment-resistant depression, anxiety, and certain presentations of obsessive-compulsive disorder.

How it works

The primary mechanism of both generations is blockade of dopamine D2 receptors in the mesolimbic pathway — the neural circuit most directly implicated in psychotic symptoms like hallucinations and delusions. Elevated dopamine signaling in this pathway correlates strongly with positive symptoms of psychosis (hallucinations, paranoia, disorganized thought).

Where the two generations diverge is in selectivity and secondary receptor activity:

1. FGAs block D2 receptors broadly and with high affinity across multiple dopamine pathways, including the nigrostriatal pathway, which regulates motor control. This accounts for the class's most serious adverse effects: extrapyramidal symptoms (EPS) — muscle rigidity, tremor, akathisia — and the irreversible movement disorder tardive dyskinesia, which the American Psychiatric Association estimates affects approximately 30% of patients on long-term FGA therapy.

2. SGAs block D2 receptors with lower affinity and also antagonize serotonin 5-HT2A receptors. This serotonin component is thought to moderate motor side effects and to improve the negative symptoms of schizophrenia (flat affect, social withdrawal, reduced speech) — symptoms that FGAs address poorly. SGAs carry a different risk profile, particularly metabolic: weight gain, elevated triglycerides, and increased risk of type 2 diabetes are documented concerns for olanzapine and clozapine especially.

Clozapine occupies a singular position: it is the only antipsychotic with demonstrated efficacy in treatment-resistant schizophrenia, per the National Institute of Mental Health, but its risk of agranulocytosis — a potentially fatal drop in white blood cells — requires mandatory enrollment in the FDA's Clozapine REMS Program and regular absolute neutrophil count monitoring.

Common scenarios

Antipsychotics appear across a surprisingly wide clinical landscape. The most common contexts include:

• Acute psychosis — FGAs, particularly haloperidol, are frequently used in emergency settings for rapid stabilization, often via intramuscular injection, because of established dosing protocols and rapid onset.
• Schizophrenia maintenance — Long-acting injectable formulations (LAIs) of risperidone, paliperidone, and aripiprazole address the well-documented adherence problem; oral antipsychotics are discontinued within 18 months by roughly 75% of patients in naturalistic studies.
• Bipolar mania — Quetiapine and olanzapine are FDA-approved for acute mania and have largely replaced older regimens in many practices.
• Adjunctive depression treatment — Aripiprazole, quetiapine, and brexpiprazole carry FDA augmentation indications for major depressive disorder that hasn't responded to antidepressants alone.
• Pediatric and adolescent contexts — Risperidone holds FDA approval for irritability associated with autism spectrum disorder in children as young as 5, a use examined closely in the mental health in children and adolescents literature given metabolic concerns in developing bodies.

Decision boundaries

Choosing between an FGA and an SGA — or among SGAs — involves weighing mechanisms against individual patient factors rather than declaring a universal winner.

FGA vs. SGA: The movement disorder risk of FGAs is real and sometimes irreversible. For patients without prior EPS history, an FGA's lower cost and decades of safety data remain legitimate considerations, particularly in low-resource settings. Where metabolic risk is already elevated — pre-diabetes, obesity, cardiovascular history — many prescribers avoid olanzapine or clozapine regardless of their efficacy profile.

Clozapine's threshold: The monitoring burden is substantial, but for patients who have failed 2 adequate trials of other antipsychotics, the evidence base for clozapine is stronger than for any alternative. Underuse of clozapine in treatment-resistant cases is a recognized gap in care, documented in the medication for mental health clinical literature.

LAIs vs. oral dosing: Non-adherence to oral antipsychotics is the single most common cause of relapse in schizophrenia. Long-acting injectables remove the daily decision point entirely, which matters more for some patients than any pharmacological difference between agents.

Monitoring requirements differ sharply by agent — metabolic panels for SGAs, movement assessments for FGAs, and the specialized neutrophil monitoring unique to clozapine. Coordinating this alongside broader support, including psychotherapy types and approaches and community mental health centers, reflects current standard practice for chronic psychotic illness. None of these medications works in isolation from the rest of a person's life.